PolyNovo share price jumps despite the market selloff amid heavy insider buying

The S&P/ASX 200 Index (ASX: XJO) is a sea of red on Friday but that hasn't stopped the PolyNovo Ltd (ASX: …

| More on:
A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The PolyNovo share price is charging higher despite the market selloff
  • News of insider buying appears to have boosted the medical device company's shares
  • PolyNovo's chair picked up 500,000 shares through an on-market trade on Thursday

The S&P/ASX 200 Index (ASX: XJO) is a sea of red on Friday but that hasn't stopped the PolyNovo Ltd (ASX: PNV) share price from charging higher.

In afternoon trade, the medical device company's shares are up 6% to 92 cents.

Why is the PolyNovo share price racing higher?

The PolyNovo share price has avoided the market selloff today after it emerged that insiders have been buying the company's shares.

According to two change of director's interest notices, PolyNovo's chairman and a non-executive director have both been buying shares.

The first notice reveals that chairman David Williams picked up 500,000 shares through an on-market trade on Thursday. Mr Williams paid an average of $0.8689 per share, which represents a total consideration of $434,450.

The other notice shows that non-executive director Andrew Lumsden bought 100,000 shares through an on-market trade on the same day. Mr Lumsden paid an average of $0.8731 per share, which represents a total consideration of $87,310.

Based on these purchases, these insiders appear to believe the PolyNovo share price is good value after hitting a multi-year low of 84 cents earlier this week.

Analysts at Macquarie are likely to agree with that view. Last month, the broker put an outperform rating and $1.60 price target on the company's shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »